Argen X SE - ADR

Significant Revenue Growth: In Q4 2025, argenx reported product net sales of $1.3 billion, marking a 90% year-over-year growth. For the full year, net sales reached $4.2 billion, highlighting strong demand and prescriber confidence, particularly spurred by the successful launch of the prefilled syringe (PFS) for self-injection.

Positive Clinical Results: The company announced successful Phase III results for VYVGART in ocular myasthenia gravis, meeting primary endpoints with a statistically significant improvement in patient-reported outcomes (p-value of 0.012). This positions VYVGART to expand its label, potentially addressing a market of 7,000 additional patients.

Growth Opportunities Ahead: The company anticipates further growth drivers from additional indications such as seronegative MG, autoimmune myositis, and Sjogren's disease. Key upcoming milestones include the PDUFA date for seronegative MG on May 10, which could augment their addressable market by 11,000 patients.